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Abstract
Objective: To assess whether treatment outcomes vary with age for adults receiving antiretroviral therapy (ART) in a large
rural HIV treatment cohort.
Design: Retrospective cohort analysis using data from a public HIV Treatment & Care Programme.
Methods: Adults initiating ART 1st August 2004 - 31st October 2009 were stratified by age at initiation: young adults (16–24
years) mid-age adults (25–49 years) and older ($50 years) adults. Kaplan-Meier survival analysis was used to estimate
mortality rates and age and person-time stratified Cox regression to determine factors associated with mortality. Changes in
CD4 cell counts were quantified using a piecewise linear model based on follow-up CD4 cell counts measured at six-
monthly time points.
Results: 8846 adults were included, 808 (9.1%) young adults; 7119 (80.5%) mid-age adults and 919 (10.4%) older adults, with
997 deaths over 14,778 person-years of follow-up. Adjusting for baseline characteristics, older adults had 32% excess
mortality (p = 0.004) compared to those aged 25–49 years. Overall mortality rates (MR) per 100 person-years were 6.18 (95%
CI 4.90–7.78); 6.55 (95% CI 6.11–7.02) and 8.69 (95% CI 7.34–10.28) for young, mid-age and older adults respectively. In the
first year on ART, for older compared to both young and mid-aged adults, MR per 100 person-years were significantly
higher; 0–3 months (MR: 27.1 vs 17.17 and 21.36) and 3–12 months (MR: 9.5 vs 4.02 and 6.02) respectively. CD4 count
reconstitution was lower, despite better virological response in the older adults. There were no significant differences in MR
after 1year of ART. Baseline markers of advanced disease were independently associated with very early mortality (0–3
months) whilst immunological and virological responses were associated with mortality after 12months.
Conclusions: Early ART initiation and improving clinical care of older adults are required to reduce high early mortality and
enhance immunologic recovery, particularly in the initial phases of ART.
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Introduction
Older adults ($50 years old) comprise a significant proportion
of people enrolling in HIV treatment programmes in sub-Saharan
Africa yet outcomes after initiation of antiretroviral therapy (ART)
for this group have not been well described. Older adults have
generally been neglected in addressing the global HIV epidemic
[1]. Indeed, reporting mechanisms and estimates of epidemiolog-
ical trends usually only encompass adults aged 15–49 [2].
UNAIDS estimated that globally there were 2.8 million adults
aged 50 years and older living with HIV in 2005 [3]. Data from
our surveillance programme in rural KwaZulu-Natal estimates
overall HIV prevalence rate at 9.5% and incidence of 1% in adults
aged 50 years and older [4]. In a verbal autopsy study in rural
Kenya, HIV was the cause of death in 27% of people aged 50
years and older and was the leading cause of death up to the age of
70 years [5].
Age is a major determinant of mortality for many diseases in the
absence of HIV and ART [6]. In the pre-antiretroviral therapy
(ART) era, data from sub-Saharan Africa showed that older age at
seroconversion was associated with more rapid progression to
death [7,8,9,10]. Since the introduction of ART, there have been
conflicting data on outcomes for older individuals. Assessing age as
a continuous variable, two studies have suggested an association
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between increasing age and higher mortality on ART [11,12].
Two studies analysing age as a categorical variable have reported
significantly higher mortality for individuals aged .50 years: the
ART-LINC cohort in an analysis of 7160 patients from 10 sites
reported a two-fold increased risk in overall mortality for those
$50 years compared to 16–29 year olds [13]; while in the South
African Free State programme there was 58% increased risk of
mortality for adults .50 years compared to 20–29 year olds,
although the mortality also included people dying before ART
initiation [14]. Other studies including a 7 year cohort in Senegal
have reported no clear association between age and mortality on
ART [15,16,17,18,19]. Comparison across studies is complicated
by the use of different age categories. Moreover these studies have
included age as an explanatory variable rather than explicitly
assessing mortality within and between younger and older ages.
ART outcomes including mortality, immunological and virological
response may potentially be influenced by age [20,21] hence it is
important to understand treatment outcomes to inform on
appropriate HIV management in older adults. We aim to
explicitly assess how mortality rates following ART initiation
compare between older and younger adults and the factors
associated with mortality in each age category using data from a
large rural HIV Treatment and Care cohort and to quantify
immunological and virological responses in different age groups.
Methods
Ethics statement
Written informed consent was obtained from all participants in
the programme to allow use of anonymised routine clinical data in
research. Ethical approval for retrospective analysis of these data
was obtained from the Biomedical Research Ethics Committee of
the University of KwaZulu-Natal (BE066/07) and the Research
Office of the KwaZulu-Natal Department of Health.
Hlabisa HIV Treatment and Care Programme. The
Hlabisa HIV Treatment & Care Programme is a partnership
between the local Department of Health (DoH) and the Africa
Centre for Health and Population Studies (www.africacentre.ac.
za). The details of the programme have been previously described
[22,23].
The programme adheres to the national antiretroviral treatment
guidelines which at the time of study recommended initiation of
ART for adults with WHO stage IV disease or CD4 cell count
#200 cells/mm3 [24]. Co-trimoxazole was indicated for all
individuals with CD4 count #200 cells/mm3 or WHO stage 3/4.
First-line ART consisted of stavudine (d4T), lamivudine (3TC), and
either efavirenz (EFV) or nevirapine (NVP). ART was initiated at
primary health care (PHC) clinics (or at Hlabisa district hospital) by
a physician; monitoring and ART dispensing was subsequently
performed by nurses and counsellors. CD4 cell count and HIV viral
load were measured every 6 months on ART.
Data acquisition. Clinical information at baseline and at
monthly clinic visits after initiation of ART is transferred from
standardised clinic records to a centralised MicrosoftH Access
database. A comprehensive tracking service operates whereby
patients who are more than one week late for their clinic visit are
contacted by telephone and, if necessary, visited at home by a
tracker nurse. Information pertaining to death after initiation of
ART is therefore obtained either by the clinic staff or tracker team
through communication with family members, other clinic staff, or
hospital staff. Cause of death is recorded if known but not
systematically sought within the routine programme. Laboratory
results (CD4 cell count and HIV viral load) are regularly updated
from the National Health Laboratory Service (NHLS) laboratory
at a district hospital (Hlabisa Hospital). CD4 counts were analysed
using the Beckman Coulter EPICSH XL flow cytometer (Beckman
Coulter, Inc.). Viral load was measured at a provincial laboratory
using the NucliSens EasyQH HIV-1 assay (bioMe´rieux), with a
lower detection limit of 25copies/ml.
Data analysis. Analysis included all adults ($16 years) who
initiated ART between 1st August 2004 and 31st October 2009,
excluding patients on ART who transferred into the programme
from elsewhere. Analysis was stratified by age at initiation (,50
years and $50 years), a classification which ensured consistency
with previous reports [21]. The ,50 years age group was further
stratified into 16–24 years and 25–49 years to assess for
heterogeneity in overall outcomes and baseline descriptions. We
assessed differences between the three groups in baseline clinical
characteristics using the non-parametric equality-of-medians test
for continuous variables and proportions test for categorical
variables. Estimated glomerular filtration rate (eGFR) was
calculated using the 4-variable Modification of Diet in Renal
Disease (4-v MDRD) equation, without the ethnicity correction
factor, as validated in a South African population [25,26].
Kaplan-Meier survival analysis was used to assess and compare
mortality between and within age strata. Data was censored at earliest
of date of death, date of loss to follow-up, date of transfer out of
programme, or 22nd April 2010. Loss to follow-up was defined as
three consecutive months without a clinic visit. To ascertain the
independent influence of age on overall mortality, a Cox regression
model adjusted for all significantly different baseline factors (P,0.05)
was used to assess mortality hazard difference by age strata. The two
bottom age strata (young and mid-age groups) were combined in the
analysis for determination of mortality risk factors because there were
no statistically significant mortality outcome differences between the
two groups. This is also consistent with previous analysis that have
assessed those aged below 50 years as one group in comparison to
those aged 50 years and above [27,28,29,30]. Stratified Cox
regression with time split at 3 and 12 months post-ART initiation
was used to determine risk factors for mortality in the periods 0–3
months (very early mortality), 3–12 months (early mortality), and
.12 months post-ART initiation. For the two periods in the first
year, analysis was further stratified by age to establish differences in
mortality predictors between old and young patients. For all Cox
models, variables that were associated with mortality at 15%
significance level were individually included into the model and
model goodness-of fit assessed. Validity of the proportional hazards
assumption was tested using the score test based on scaled Schoenfeld
residuals [31]. All results are reported at 5% significance level.
Changes in CD4 cell counts in the 24 months following ART
initiation were quantified using a piecewise linear model based on
follow-up CD4 cell counts measured at six-monthly time points 6
three months. For 909 and 504 patients with missing CD4 counts
at 6 months and 12 months respectively the value was interpolated
from their CD4 cell counts immediately before and after that time
point. Of the 2977 patients alive and active 12 months post ART
initiation, 2187 patients (73.5%) had a recorded CD4 count.
Virological response at one year was based on viral load
measured between 6 and 15 months after ART initiation. The
effect of suboptimal virological response (defined as viral load
$400 copies/ml) on mortality after the first year of ART was
quantified in a Cox regression model adjusted for baseline
variables and follow-up CD4 cell counts. For both viral loads
and CD4 counts, where more than one measurement was
available within the specified time period, the one closest to that
time point was used.
Sensitivity analysis. To account for the effect of missing
baseline and follow-up explanatory data, we assessed for any
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differences in mortality in those with missing observations
compared to those with recorded observations. Where those
with missing data had significantly different mortality rates, we
maintained a category of the missing group within the respective
variable in both the univariable and multivariable models
exploring factors associated with mortality. This adjusted for any
overestimation of the effect of measured/recorded variables on
mortality in the absence of those with unmeasured/missing
variables. To assess for the extent of loss to follow up bias, we
conducted sensitivity analyses where patients lost were considered
dead. All analyses were performed with STATA version 11.0
(College Station, Texas, USA).
Results
Patient characteristics
Between 1st August 2004 and 31st October 2009, 8846 adults
initiated ART in the programme. Of these, 808 (9.1%) were aged
16–24 years, 7119 (80.5%) were aged 25–49 years and 919
(10.4%) were $50 years at time of ART initiation (range 16–83
years). Overall median baseline CD4 cell count was 119cells/ml
(IQR 58–174). Older adults had the lowest proportion with CD4
cell count ,50cells/ml prior to ART initiation and the highest
median CD4 count was amongst those aged 16–24 years (Table 1).
Mortality
There were 997 deaths in 14,778 person-years of follow-up (72 in
adults aged 16–24 years; 790 in adults 25–49 years and 135 in adults
$50 years at ART initiation). The overall mortality rate was 6.75 per
100 person-years (95% confidence interval [CI] 6.34–7.18),
significantly higher for $50 year old adults (8.69 per 100 person-
years, 95% CI 7.34–10.28) than younger adults (6.18 per 100
person-years, 95% CI 4.90–7.78 and 6.55 per 100 person-years,
95% CI 6.11–7.02 in those age 16–24 years and 25–49 years old
respectively). Overall, controlling for baseline differences (sex, WHO
disease stage, baseline CD4 cell count, haemoglobin, weight, eGFR,
education and employment) there was 32% excess mortality risk in
patients aged $50 years (aHR 1.32, 95% CI 1.09–1.60, P=0.004)
compared to those aged 25–49. There were no significant differences
in either overall mortality or time stratified mortality rates between
those initiating aged 16–24 and those aged 25–49 (Table 2).
In all age groups, the majority of deaths (769 deaths, 77.1%)
occurred in the first year after ART initiation, with mortality
particularly high in the first three months after ART initiation (449
deaths, 45.0%). Figure 1A (Kaplan-Meier curve) illustrates
mortality differences between the two age groups. Early mortality
rates were significantly higher for older adults ($50 years) but there
was no significant mortality difference after 12 months (Table 2).
Immunological response
Despite baseline CD4 cell count being higher for older adults;
their median CD4 cell count post-ART initiation was lower than
for both groups of younger adults at each time point (Figure 2A).
Overall 16.6% had a poor immunological response (failed to
achieve a CD4 count increase of $50 CD4 cells) in the first 6
months of therapy with the largest proportion being in those aged
Table 1. Baseline characteristics for individuals initiated on ART August 2004 - October 2009 (n = 8846), stratified by age at ART
initiation.
Variable 16–24 years 25–49 years 50+years
N
% or
median (IQR) (95% CI) N
% or
median (IQR) (95% CI) N
% or
median (IQR) (95% CI)
Age 808 22 (21–24) 7119 35 (30–40) 919 54 (51–58)
Male sex 107 13.24 10.90–15.58 2504 35.17 34.06–36.28 400 43.5 40.32–46.73
WHO stage 3 or 4 328 40.59 37.21–43.98 3435 48.25 47.09–49.41 420 45.70 42.48–48.92
Missing 357 44.18 40.76–47.61 2629 36.93 35.81–38.05 348 37.87 34.73–41.00
CD4 cell count, cells/ml
Median (IQR) 777 133 (69–182) 125.7–144 6827 115 (55–173) 113–118 888 127 (71–177) 122–136
150–200 220 28.31 25.14–31.48 1643 24.07 23.05–25.08 237 26.69 23.78–29.60
100–149 162 20.85 17.99–23.71 1449 21.22 20.25–22.19 221 24.89 22.04–27.73
50–99 139 17.89 15.19–20.59 1431 20.96 20.00–21.93 178 20.05 17.41–22.68
,50 138 17.76 15.07–20.45 1540 22.56 21.57–23.55 138 15.54 13.16–17.93
.200 118 15.19 12.66–17.71 764 11.19 10.44–11.94 114 12.84 10.64–15.04
Viral load, log10 copies/ml 491 4.38 4.26–4.56 4313 4.40 4.36–4.43 542 4.53 4.43–4.63
Weight, kg (IQR) 704 56 54.7–57.1 6262 59.3 59–59.8 814 60 59.1–61
TB treatment 171 21.16 18.34–23.98 1581 22.21 21.24–23.17 175 19.04 16.50–21.58
Haemoglobin ,8 g/dL 76 9.41 7.39–11.42 576 8.09 7.46–8.72 44 4.79 3.41–6.17
Missing 110 13.61 11.25–15.98 914 12.84 12.06–13.62 101 10.99 8.97–13.01
*eGFR #60 ml/min/1.73 m2 30 3.71 2.41–5.02 854 12.00 11.24–12.75 311 33.84 30.78–36.90
Missing 93 11.5 9.3–13.7 725 10.2 9.5–10.9 86 9.4 7.5–11.2
Albumin ,32 g/L 440 54.46 51.02–57.89 3764 52.87 51.71–54.03 474 51.58 48.34–54.81
Missing 98 12.13 9.88–14.38 767 10.7 10.05–11.49 93 10.12 8.17–12.07
CI, confidence interval; IQR, interquartile range.
*eGFR, estimated glomerular filtration rate: calculated using 4-variable MDRD equation (without ethnicity correction).
doi:10.1371/journal.pone.0021795.t001
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50 years and above (19.6% vs 11.1 and 16.9 in 16–24 year olds
and 25–49 years olds respectively). Almost half of all those who
initiated with CD4 cell count ,50 cells/ml (45.2%) failed to attain
a CD4 cell count .200 cells/ml at 12 months. Proportions with
CD4 cell counts below 200 cells/ml at specified time points post
ART initiation are displayed in Figure 2B.
Virological suppression
From the 5625 patients recorded as active at 12 months post-
ART initiation, 3809 (67.8%) viral loads were available for
analysis. Overall 86.3% had a good virological response (,400
copies/ml). A greater proportion of older adults (90.1%, 95% CI
84.7–87.0) had a good response compared to younger adults
(81.7%, 95% CI 77.4–86.1 and 86.2%, 95%CI 85.0–87.5 in 16–
24 year olds and 25–49 year olds respectively).
Factors associated with mortality
0–3 months. Using age stratified and time split analysis, from
the total 997 deaths, 449 occurred in the first three months after
ART initiation (very early mortality) giving the highest period
mortality rates of 20.9 and 27.1 per 100 person years in younger
and older adults respectively (P = 0.037). However, although
mortality risk was significantly higher in the older age group,
within each age group, age did not have an independent
association with mortality. There was strong evidence of an
association between male sex, markers of advanced disease at
initiation (CD4 cell count ,50 cells/ml, higher log10 viral load,
lower weight, and albumin ,32 g/L) and increased very early
mortality in both age groups. In younger adults, but not in older
adults, there were additional associations with WHO stage 3/4,
low haemoglobin, and renal impairment (Table 3).
3–12 months. Three hundred and twenty deaths; 269 (12.8%)
in younger and 51 (20%) in older adults occurred between 3–12
months (early mortality), mortality rates remaining higher in older
compared to younger adults (9.5 vs 5.8 per 100 person years
respectively; p=0.001). Low baseline CD4 cell count (,50 cells/ml)
remained independently associated with mortality in those aged
,50years, as did WHO stage3/4 disease and low albumin. For older
adults the only factor independently associated with mortality in this
period was haemoglobin,8 g/dL. There remained a trend towards
increased mortality risk with CD4 cell count ,50 cells/ml and
albumin ,32 g/dL but the low numbers of deaths in this period for
older adults (n= 51) likely limited statistical power (Table 3).
After 12 months. Factors associated with mortality after 12
months were explored in a single model incorporating all ages because
of the similar mortality rates in both age strata. As such in the adjusted
model (Table 4) mortality risk was not significantly different for older
adults compared to younger adults (adjusted hazard ratio [aHR] 1.01,
95% CI 0.66–1.55). There was no longer any evidence of an
association with baseline CD4 cell count, but a lower absolute CD4 cell
count and a reduced increment at 12 months post ART initiation were
both associated with higher mortality.
In all models there was no statistically significant association
between mortality and either education or employment.
Table 2. Mortality rates following ART initiation stratified by age at initiation and cohort period time (N = 8846).
Cohort period (years) Person-time (years) Failures Mortality rate 95% CI
16–24 years
0–0.25 186.34 32 17.17 12.14–24.28
.0.25–1 447.76 18 4.02 2.53–6.38
.1–2 340.94 13 3.81 2.21–6.57
.2 190.76 9 4.72 2.45–9.07
25–49 years
0–0.25 1675.67 358 21.36 19.26–23.70
.0.25–1 4166.90 251 6.02 5.32–6.82
.1–2 3478.11 111 3.19 2.65–3.84
.2 2737.47 70 2.56 2.02–3.23
$50 years
0–0.25 217.64 59 27.11 21.00–35.00
0.25–1 535.77 51 9.52 7.23–12.53
.1–2 445.10 15 3.37 2.03–5.59
.2 355.74 10 2.81 1.51–5.22
TOTAL 14778.19 997 6.75 6.34–7.18
doi:10.1371/journal.pone.0021795.t002
Figure 1. Age and mortality risk post ART initiation. Kaplan-
Meier plot of cumulative mortality probability after initiation of ART,
stratified by age group at time of ART initiation.
doi:10.1371/journal.pone.0021795.g001
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Figure 2. Age and immune response to ART. A. Median CD4 cell count (cells/ml) over time since ART initiation, stratified by age at ART initiation.
B. Proportion of patients failing to achieve a CD4 count .200 cells/ul at pre-defined time points post ART initiation, stratified by age at initiation.
doi:10.1371/journal.pone.0021795.g002
Table 3. Independent risk factors for very early (0–3 months after ART initiation) and early (3–12 months) mortality stratified by
age.
Variable Very early mortality (0–3 months) Early mortality (3–12 months)
,50 years (n=7927) $50 years (n =919) ,50 years (n =7154) $50 years (n=832)
Age (1yr increase) 0.99 (0.95–1.04) 1.03 (0.99–1.08)
25–49 years 1 1
16–24 years 0.79 (0.54–1.34) 0.73 (0.45–1.19)
Male sex 1.64 (1.32–2.03) 1.84 (1.06–3.17) 1.40 (1.09–1.80) 1.33 (0.73–2.41)
WHO stage 3 or 4 1.77 (1.11–2.81) NS 2.06 (1.19–3.57) NS
CD4 cell count (cells/ml)
150–200 1 1 1 1
100–149 1.22 (0.79–1.88) 1.03 (0.37–2.86) 1.04 (0.65–1.68) 1.73 (0.70–4.26)
50–99 1.57 (1.05–2.33) 2.34 (0.97–5.67) 1.50 (0.97–2.31) 1.97 (0.79–4.87)
,50 2.38 (1.63–3.46) 2.60 (1.07–6.31) 2.76 (1.85–4.10) 2.00 (0.80–4.98)
.200 1.56 (0.96–2.52) 1.19 (0.35–4.05) 1.50 (0.90–2.51) 2.19 (0.83–5.82)
Missing 2.12 (1.16–3.87) 3.97 (1.10–14.4) 1.80 (0.92–3.51) 0.30 (0.04–2.63)
Viral load (per log10 increase) 1.16 (1.03–1.34) 2.28 (1.52–3.43) NS NS
Weight (1kg increase) 0.94 (0.93–0.95) 0.96 (0.94–0.99) 0.99 (0.97–1.00) NS
TB treatment* 1.59 (0.84–1.97) 0.90 (0.48–1.69) 1.05 (0.79–1.40) 1.38 (0.72–2.63)
Haemoglobin ,8g/dL 2.06 (1.61–2.64) NS NS 4.15 (1.79–9.65)
eGFR #60 ml/min/1.73m2{ 1.73 (1.35–2.23) NS 1.41 (1.00–1.98) NS
Albumin ,32g/L 3.58 (2.44–5.24) 2.56 (1.19–5.58) 2.17 (1.56–3.02) 1.52 (0.76–3.02)
missing 4.38 (1.88–10.19) 0.67 (0.42–10.58) NS NS
Cox regression models split by time under observation (person years) into very early mortality (0–3 months) and early mortality (3–12 months). Risk factors determined
separately for age groups ,50 years and $50 years.
All values are adjusted hazard ratios with 95% confidence interval.
NS, not significant in univariable model.
*Concurrent TB treatment at time of ART initiation.
{eGFR, estimated glomerular filtration rate: calculated using 4-variable MDRD equation (without ethnicity correction).
doi:10.1371/journal.pone.0021795.t003
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Sensitivity analysis
Mortality rates did not differ significantly between those with
complete baseline observations compared to those with missing
observations. However 116 (6.4%) of 1816 patients alive but with a
missing viral load at 12 months subsequently died compared to
112 (2.9%) of 3809 with a recorded viral load (P,0.001), whilst
103 (7.1%) of those alive but with a missing CD4 cell count at 12
months post ART initiation died compared to 125 (3.0%) of those
with a recorded CD4 count (P,0.001), resulting in higher
mortality risk in some of these missing categories (Table 4).
Overall loss to follow-up was 12.9%; 11.6% and 6.5% in the
16–24 yrs, 25–49 yrs, and $50 yrs age groups respectively
(p,0.01). Despite these differences, the sensitivity Kaplan Meier
and Cox regression analysis results did not differ significantly from
those obtained using completely observed data.
Discussion
We used a large rural HIV treatment programme in South
Africa, with a comprehensive tracking system for patients lost to
follow-up, to assess mortality rates and differences in three
population groups defined by age. In this analysis of 8846 adults
with 997 deaths, overall mortality risk was 32% higher for those
who initiated ART at age $50 years compared to those initiating
at age 25–49. Although consistent with previous reports from
urban African settings [13,14] we show that this mortality
difference is only evident in the first year of ART, following
which mortality rates in older adults are no longer different from
that in younger adults despite only modest CD4 count
reconstitution in the older age group. Previous studies from
Europe and North America [32,33,34,35] have also reported
poorer immunological but better virological responses in older
compared to younger adults but have not explored how these may
relate to mortality rates in older age groups receiving ART. Our
study shows that despite older adults having a lower proportion of
individuals achieving good immunological response in the first
year on ART, their mortality rate as a group, after 12 months on
ART, was similar to that observed in the younger adult group.
This finding coupled with the fact that older adults had a higher
proportion of individuals achieving optimal viral suppression,
might imply that in older adults, the degree of CD4 count
reconstitution may matter less once HIV has been suppressed.
Mortality was not significantly associated to either education or
employment probably because in this population there is not much
heterogeneity in socio-economic variables and everyone is poor
[22].
The majority of people enrolled in HIV care and treatment
programmes in sub-Saharan Africa are younger adults, consistent
with prevalence patterns [37]. In this programme, just over 10% of
adults who initiated ART during the study period were $50 years
old. The higher proportion of males is contrary to the treatment
programme in general but is consistent with local prevalence data
that shows more males being infected later in life hence expected
to access care much later than females [4,23]. Whilst evidence
from high-resource settings has suggested that older adults present
with more advanced disease [33,38,39], our data suggest the
opposite with a higher median CD4 cell count and lower
proportion with CD4 cell count ,50 cells/ml in older adults.
The most striking clinical difference between the groups at
baseline was the higher proportion of renal dysfunction at baseline,
with 37% of older adults having an estimated glomerular filtration
rate (eGFR) of #60 ml/min/1.73 m2. Consistent with the
observed decline in GFR with age, this alerts us to the high
frequency of renal disease in this setting which is not always
detected with serum creatinine measurements alone [40].
In all age groups, the highest mortality rates were in the first
three months of ART in line with data previously published from
this and other programmes [23,41,42,43,44]. Very early and early
mortality was higher in older adults, although older adults
presented for ART initiation with higher CD4 counts than
younger adults. High early mortality mainly associated with
Table 4. Independent predictors of mortality after the first 12
months of ART (N = 5625).
Variable aHR 95% CI
Age 25–49 years 1
$50 years 1.01 0.66–1.55
16–24 years 1.35 0.86–2.14
Male sex 1.95 1.46–2.57
Baseline WHO stage 3/4 2.72 1.49–4.97
Missing 2.62 1.43–4.83
Baseline CD4 cell count (cells/ml)
150–200 1
100–149 0.80 0.51–1.25
50–99 1.11 0.72–1.71
,50 1.11 0.70–1.75
.200 0.65 0.38–1.13
Missing 0.46 0.20–1.06
Weight (1 kg increase) 0.98 0.96–0.99
Albumin ,32 g/L 1.77 1.27–2.47
CD4 increment at 6months (cells/ml)
,50 1
50–99 0.98 0.63–1.51
$100 0.49 0.29–0.81
Missing 1.33 0.39–4.59
Absolute CD4 count at 6months
(cells/ml)
.350 1
201–350 1.45 0.81–2.57
#200 0.91 0.44–1.90
CD4 increment at 12months (cells/ml)
,50 1
50–99 0.41 0.23–0.73
$100 0.46 0.24–0.88
Missing 6.15 1.69–22.38
Absolute CD4 count at 12months
(cells/ml)
.350 1
201–350 0.81 0.43–1.54
#200 1.49 0.73–3.03
Viral load at 12months (copies/ml)
,400 1
$400 2.67 1.78–4.02
Missing 1.74 1.26–2.41
aHR, adjusted hazard ratio; CI, confidence interval.
Risk factors determined through Cox proportional hazards regression
techniques, assessing mortality after 12 months post ART initiation, conditional
on being active on the treatment programme at 12 months.
doi:10.1371/journal.pone.0021795.t004
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advanced disease coupled with blunted immunologic response in
older adults raises an important question of whether older adults
should initiate ART at higher CD4 count threshold compared to
younger adults and calls for interventions to encourage early
presentation for ART. Older adults may also potentially benefit
from enhanced clinical care during initial phases of ART.
The high number of deaths immediately after ART initiation
suggests that this mortality is still driven largely by HIV disease itself.
However, for older adults, the higher mortality may be explained by
higher prevalence of non-HIV conditions such as cardiovascular
diseases and diabetes. Unfortunately we were unable to ascertain
the cause of death since this information within the programme was
extremely limited, with only 42 of 997 deaths (4.2%) attributed to a
specific cause. However, research in similar settings has shown
mortality in the first year of ART to be caused predominantly by
infectious diseases related to immunosuppression with tuberculosis
consistently shown to be the leading cause of death across all age
groups followed by cryptococcal disease and other infectious
diseases [18,19,44,45]. Although in previous analyses we showed
that younger age was associated with higher TB incidence in the
first three months of ART [36], it could be that TB presentation is
different in older adults or that symptoms are less frequently
attributed to TB in this group leading to missed diagnoses and
mortality [46]. The contribution of immune reconstitution
inflammatory syndrome (IRIS) to early mortality remains unclear;
a recent meta-analysis, using data from diverse settings across high-,
middle- and low-income settings, suggested that IRIS might be
responsible for 21% of all deaths after ART initiation [47]. Whether
the incidence, presentation or mortality attributable to IRIS is
higher in older adults requires further study.
Our study demonstrates that at 12 months, approximately one-
quarter of our cohort had CD4 cell count #200 cells/ml with the
largest proportion and the poorest immunological response in those
aged $50 years and this was associated with increased risk of
subsequent death. Larger CD4 count increases were significantly
associated with reduced mortality risk irrespective of recent absolute
CD4 count. In addition previous absolute CD4 cell thresholds (CD4
cell count at 6 months after ART initiation) were not associated with
mortality although CD4 count increments of greater than 100 cells/
ml at this stage decreased mortality risk beyond a year on therapy.
This may possibly imply that as long as there is an immune response
greater than a certain threshold, the influence of the absolute CD4
cells count on mortality becomes minimal and non-significant.
Despite younger adults demonstrating superior immunological
responses, they had inferior virological suppression, a finding that
supports previous observations [32,33,34,35], and was associated
with a nearly threefold increased risk of mortality after the first year
on therapy. Hence the increased risk in older adults associated with
poorer immunologic response may have been counteracted by the
reduced risk associated with superior virological response resulting
in equal mortality risk in both age groups after one year of ART.
Although it is possible that this lack of mortality difference may be
due to limited statistical power, there are also possible reasons why
this may be; the fact that these older adults are seen every 30 days by
health care personnel when they come to collect ART may mean
that they have a better chance of early diagnosis of age driven
morbidities and better clinical management of new and existing
morbidities hence limiting the effect of age on mortality. Babiker et
al previously suggested that the effect of age on mortality could be
attenuated in the HAART era if there was proportionately a
reduction in mortality in older age groups. As older adults are at
higher risk of HIVmortality primarily due to a faster decline in CD4
cell counts, HAART associated increases in CD4 could have a
larger impact in reducing mortality in an older population [6].
Our study population is similar to that from many rural public
health HIV treatment programmes and therefore our results are
likely generalisable to similar settings in sub-Saharan Africa. The
large cohort size and high mortality rates have enabled this analysis
[23]. A major strength of our programme is the comprehensive
tracking system for patients lost to follow-up which ensures that
deaths are ascertained contemporaneously, unlike in many other
programmes [48], giving us confidence that our mortality rates are
representative of the true population mortality rates.
Our study has certain limitations as a retrospective analysis of
routine programmatic data; we were hampered by missing results
particularly for follow-up CD4 cell counts and viral loads which
we attempted to address by interpolation of missing CD4 cell
counts. The blunted immunological response in older adults
compared to younger adults might have been underestimated
because CD4 cell count changes are influenced by survival bias,
i.e. individuals with the worst immunological response are more
likely to have died. Although we controlled for multiple biological
variables in determining factors associated with mortality, there
might still be residual confounding by adherence levels or other
unmeasured variables.
Extremely high mortality rates in the first year of ART, more so
for older adults suggests that strategies to reduce this early
mortality need to be implemented and evaluated with a degree of
urgency and that the needs of older adults should be considered
within these strategies. Medical interventions, particularly inten-
sive screening and treatment for TB and cryptococcal infection
should be implemented and evaluated to improve understanding
of the epidemiology of these infections in older adults [49]. Better
understanding of the current patterns of testing and health care
usage amongst older adults will inform on appropriate age-specific
interventions. Making HIV services more acceptable for this age
group might get them into HIV care at an earlier stage. We have
previously shown lower rates of retention in pre-ART care for
older adults [50]; with the known association between older age
and more rapid CD4 decline, it is necessary to explore alternative
care strategies, which might include integration with other chronic
disease management or community-based follow-up [51]. Further
work is ongoing within our programme to determine the causes of
death and the burden of co-morbidities in the older population.
Future work is required to evaluate whether more intensive follow-
up impacts on mortality for individuals at high-risk of death in the
first few months of ART.
Discussion around older adults and the HIV epidemic in sub-
Saharan Africa often only focus on the indirect impact of the
epidemic. Our finding of higher mortality on ART for older adults
compared to younger adults adds to the evidence base pointing to
a substantial direct effect of HIV on older adults’ health. As we
move into the next phase of ART scale-up the challenges of HIV
in older people will need to be addressed with more purpose.
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